Terlipressin

What is Terlipressin?

Terlipressin is a synthetic, long-acting analogue of vasopressin used in hospital for two complications of advanced cirrhosis: hepatorenal syndrome with acute kidney injury, and bleeding from oesophageal varices. It is given intravenously, in an intensive care or high-dependency setting, and is never a self-administered or outpatient drug. Structurally it is lysine-vasopressin with three glycine residues bolted onto the N-terminus. The FDA label describes it as a 12-amino-acid peptide with the chemical name N-[N-(N-glycylglycyl)glycyl]-8-L-lysine-vasopressin, molecular formula C52H74N16O15S2 and an average molecular weight of 1227.38 as the free base. Those three extra glycines are the entire design idea. They make terlipressin a prodrug: tissue peptidases clip them off steadily over hours, releasing lysine-vasopressin as the major active metabolite, so a drug with a 54-minute terminal half-life generates a metabolite that keeps working for roughly three hours. That converts what would otherwise be a continuous vasopressin infusion into intermittent injections. Terlipressin is not simply an inert carrier, though. The label is explicit that it acts both as a prodrug for lysine-vasopressin and as a pharmacologically active molecule in its own right, with roughly twice the selectivity for vasopressin V1 receptors over V2 receptors. The V1 bias is what makes it useful: V1 receptors on splanchnic arteriolar smooth muscle mediate vasoconstriction, while V2 receptors in the kidney collecting duct mediate water retention and hyponatraemia, which is a side effect rather than a goal. The regulatory picture is unusual. Terlipressin has been routine European practice since the 1980s, yet the United States did not approve it until September 2022 — and when it did, the approval was narrower than European use and came with a boxed warning that European labels do not carry.

What Terlipressin Is Investigated For

Terlipressin earns its place on two indications, and the strength of the evidence is quite different for each. For hepatorenal syndrome, terlipressin is the only drug any regulator has approved anywhere, and the pivotal evidence is the CONFIRM trial (Wong et al., New England Journal of Medicine 2021). CONFIRM randomised 300 adults with type 1 hepatorenal syndrome 2 to 1 to terlipressin or placebo, both with albumin. Verified reversal of hepatorenal syndrome — two consecutive creatinine values of 1.5 mg/dL or less, with survival free of dialysis for at least 10 days afterwards — occurred in 32 percent on terlipressin versus 17 percent on placebo (P=0.006). There is a wrinkle worth knowing: the FDA label reports the same primary endpoint from the same trial as 29.1 percent versus 15.8 percent (P=0.012), a slightly different count under the agency's own analysis. Both numbers are correct for their source, so it matters which one is being cited. What CONFIRM did not show is a survival benefit. At day 90, death had occurred in 51 percent of the terlipressin group and 45 percent of the placebo group, and deaths from respiratory disorders within 90 days were 11 percent versus 2 percent. The drug reverses a kidney syndrome; it does not treat the liver failure underneath. The practical value is buying time and dialysis-free days in people waiting for a transplant. For acute variceal bleeding, terlipressin has been first-line in Europe and much of Asia for decades, and it remains the only vasoactive agent with randomised evidence of a mortality reduction in that setting — though those trials are old, small and placebo-controlled rather than head-to-head against modern endoscopic care. In practice, contemporary comparisons against somatostatin and octreotide find broadly similar haemostatic efficacy, so the choice is driven by availability and local protocol. The septic shock literature is a genuinely open question rather than an established use. Terlipressin reliably raises mean arterial pressure and spares catecholamines, but meta-analyses have not shown a mortality benefit, and the same ischaemic and respiratory risks apply.

History & Discovery

Terlipressin is a product of the mid-twentieth-century effort to make vasopressin clinically usable. Vasopressin itself was sequenced and synthesised by Vincent du Vigneaud in the early 1950s — work that won the 1955 Nobel Prize in Chemistry — but its half-life of minutes and its strong V2 activity made it awkward as a therapeutic. Lysine-vasopressin, the porcine form in which the arginine at position 8 is replaced by lysine, was the starting material. Adding a triglycyl tail to its N-terminus produced a molecule that was essentially inactive until peptidases trimmed it, converting an infusion-only drug into one that could be injected every few hours. The compound was developed in Europe under the name Glypressin and entered clinical use in the 1980s, initially for bleeding oesophageal varices. The hepatorenal syndrome indication came later and from a different direction. Through the 1990s the splanchnic vasodilatation theory of hepatorenal syndrome displaced earlier explanations, and once the problem was understood as circulatory rather than intrinsically renal, a splanchnic vasoconstrictor became the obvious intervention. European series through the late 1990s and 2000s reported reversal rates that would have been implausible a decade earlier, and terlipressin plus albumin became European standard of care well before any adequately powered trial existed. The American history is a study in how hard confirmation can be. The OT-0401 trial, reported in 2008, missed its primary endpoint. The REVERSE trial, reported in 2016, missed its primary endpoint too, though both showed improvements in creatinine. Only CONFIRM, with a redefined primary endpoint requiring verified and durable reversal, succeeded — and the FDA approved Terlivaz on 14 September 2022, roughly four decades after European clinicians started using the drug. Terlipressin remains authorised in Europe only through national procedures, with no centralised European Medicines Agency marketing authorisation, which is why the 2022 safety review had to run as an Article 31 referral decided by the CMDh rather than as a routine label change.

How It Works

In advanced cirrhosis, the arteries supplying the gut and spleen dilate dramatically. Blood pools there, the effective circulating volume falls, and the kidneys — sensing underfill — clamp down their own blood supply and stop producing urine. Terlipressin tightens the dilated gut arteries, which pushes blood back into the central circulation, raises blood pressure, and restores kidney perfusion. In variceal bleeding, the same constriction reduces blood flow into the portal system and lowers the pressure driving the bleed.

Terlipressin is a prodrug with intrinsic activity. Tissue peptidases progressively cleave the three N-terminal glycyl residues, releasing lysine-vasopressin; the FDA label is explicit that terlipressin also has pharmacologic activity of its own. Population pharmacokinetics from 69 patients with type 1 hepatorenal syndrome give a terminal half-life of 0.9 hours for terlipressin and 3.0 hours for lysine-vasopressin, with volumes of distribution of 6.3 L and 1370 L respectively. Less than 1 percent of terlipressin and less than 0.1 percent of lysine-vasopressin is excreted unchanged in urine. Because metabolism is by ubiquitous tissue peptidases rather than the liver, no dose adjustment is required for hepatic impairment, and the label states that no significant drug interactions are anticipated — in vitro work found no meaningful CYP inhibition or induction and no transporter involvement. The pharmacology rests on V1 selectivity. Terlipressin has roughly twice the selectivity for V1 over V2 receptors. V1a receptors on splanchnic arteriolar smooth muscle couple through Gq to phospholipase C, raising intracellular calcium and producing vasoconstriction in the mesenteric, splenic and hepatic arterial beds — precisely the territory that is pathologically dilated in portal hypertension. Constricting it reduces portal venous inflow, lowers the hepatic venous pressure gradient, and redistributes blood centrally. The haemodynamic consequence is measurable within minutes: after a single 0.85 mg dose the label reports an increase in mean arterial pressure and a fall in heart rate detectable within 5 minutes and sustained for at least 6 hours, with a maximum estimated effect of plus 16.2 mmHg on mean arterial pressure and minus 10.6 beats per minute on heart rate, peaking at 1.2 to 2 hours. In hepatorenal syndrome, raising mean arterial pressure is the mechanistic target rather than a side effect. Restoring effective arterial blood volume switches off the renin-angiotensin-aldosterone and sympathetic activation that drive renal vasoconstriction, and a 2026 Hepatology analysis found the relationship between achieved mean arterial pressure and hepatorenal syndrome reversal is direct. Albumin is given alongside precisely because volume expansion and vasoconstriction act on the same pathway from different directions. The liabilities follow from the same mechanism. V1 receptors are not confined to the splanchnic bed — coronary, digital, cutaneous and mesenteric constriction explain the ischaemic events, and bradycardia is a baroreflex response to the pressor effect rather than a direct cardiac action. Residual V2 agonism causes free-water retention and hyponatraemia. The respiratory signal appears to be a volume-distribution problem: venoconstriction increases central blood volume in people who already have hepatic hydrothorax, tense ascites and low oncotic pressure, and who are simultaneously receiving large daily albumin loads.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Terlipressin:

• 01Does terlipressin improve survival, or only kidney numbers? CONFIRM showed no 90-day survival benefit (51 versus 45 percent mortality), and no trial has been powered for mortality in hepatorenal syndrome. Whether reversing the syndrome translates into living longer, or simply into living with better creatinine, remains the central unanswered question.
• 02Is the respiratory signal avoidable or intrinsic? The boxed warning rests on an association, and the candidate explanations — albumin volume, baseline hydrothorax, pneumonia, venoconstriction-driven central volume shift — have not been disentangled. The 2026 real-world cohort found pneumonia was the strongest predictor (OR 7.80) while albumin dose was not, which argues against the simplest explanation.
• 03Which administration strategy should be standard? The FDA label and the European position disagree, and the randomised evidence favouring continuous infusion comes from six modest trials totalling 494 patients. A properly powered head-to-head trial of bolus versus infusion, with respiratory failure as a prespecified endpoint, does not exist.
• 04How should hepatorenal syndrome be distinguished from acute tubular necrosis at the bedside? Half of real-world terlipressin use is outside the approved indication, and response rates differ almost two-fold between phenotypes. Validated biomarkers to separate them before treatment — rather than inferring the diagnosis from the response — would change practice more than any new drug.
• 05Can responders be identified in advance? A metabolomic and proteomic analysis of CONFIRM samples has begun this work, and achieved mean arterial pressure correlates with reversal, but no prospectively validated predictor exists. Treating everyone and discontinuing non-responders on day 4 is an expensive and risk-laden way to find out.
• 06What is the role, if any, in septic shock? Terlipressin reliably raises blood pressure and spares catecholamines, and small randomised trials continue to appear, but meta-analyses have not demonstrated a mortality benefit and the ischaemic risk profile is unchanged. Whether a subgroup benefits is unknown.
• 07What happens to kidney function over months and years in people whose hepatorenal syndrome reverses but who are not transplanted? Recurrence by day 30 was common in CONFIRM, and longer-term renal trajectories are essentially undescribed.

Forms & Administration

Terlipressin is supplied as a sterile, preservative-free lyophilised powder for intravenous use. In the United States each Terlivaz vial contains 0.85 mg of terlipressin (equivalent to 1 mg terlipressin acetate) plus 10 mg mannitol, reconstituted with 5 mL of 0.9 percent sodium chloride to give 0.85 mg per 5 mL. European presentations are usually labelled as 1 mg of terlipressin acetate, and some markets supply a ready-made 0.12 mg/mL solution intended for infusion — the acetate-versus-base labelling difference is a recurring source of confusion when comparing protocols across countries. Administration is intravenous only, through a peripheral or central line; a dedicated central line is not required, and the line should be flushed afterwards. The US label specifies slow bolus injection over two minutes. European practice increasingly favours continuous infusion, which the 2022 CMDh position explicitly endorses as an alternative that may reduce severe adverse events. Reconstituted solution may be held at 2 to 8 degrees Celsius for up to 48 hours and does not need protection from light. There is no oral, subcutaneous, intranasal or compounded form, and no legitimate non-hospital supply chain. Terlipressin requires continuous pulse oximetry, serial creatinine measurement and clinical monitoring for ischaemia throughout treatment.

Dosing & Protocols

The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.

Terlipressin is a hospital-administered intravenous drug with a boxed warning for serious or fatal respiratory failure. It requires baseline and continuous pulse oximetry, serial creatinine monitoring and clinical surveillance for ischaemia. There is no legitimate outpatient, compounded or self-administered use, and the figures here are included to describe published protocols, not to guide anyone's treatment.

Timeline of Effects

Monitoring & Measurement

Common Questions

Who Terlipressin Is NOT For

Drug & Supplement Interactions

Terlipressin is unusually clean from a pharmacokinetic standpoint. It is metabolised by ubiquitous tissue peptidases rather than hepatic enzymes, is not metabolised in blood or plasma, and in vitro work in human liver microsomes found little or no evidence that it inhibits or induces any CYP enzyme or acts as an inhibitor or substrate of human ABC and SLC transporters. The label states plainly that no significant drug-drug interactions are anticipated, and that no dose adjustment is needed in hepatic impairment. The interactions that matter are pharmacodynamic rather than metabolic. Drugs that slow the heart — beta-blockers, which most patients with portal hypertension are taking for variceal prophylaxis, plus digoxin and non-dihydropyridine calcium channel blockers — compound terlipressin's baroreflex bradycardia, which occurred in 5 percent of CONFIRM patients and in none on placebo. A 2025 post hoc analysis in Alimentary Pharmacology and Therapeutics examined bradycardia and other arrhythmias specifically. Any other vasoconstrictor, including noradrenaline, midodrine and octreotide, adds to the ischaemic burden; vasopressors were prohibited during the CONFIRM treatment period for this reason. Albumin deserves separate mention because it is co-administered by design rather than by accident. The volume load is therapeutically necessary and simultaneously contributes to the respiratory risk, which is why the European position advises considering a reduced albumin dose when respiratory symptoms emerge — notably, the 2026 real-world cohort found no significant difference in albumin received between patients who did and did not develop respiratory failure, so the relationship is more complicated than a simple dose effect. Finally, residual V2 agonism means terlipressin can cause or worsen hyponatraemia, which compounds the effect of thiazide diuretics, SSRIs and desmopressin, and matters particularly in a population at risk of osmotic demyelination if sodium is then corrected quickly.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions